Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study

What this Trial Is About

Researchers are evaluating the effect and safety of different doses of the medicine NNC0662-0419 in adults living with type 2 diabetes. This phase 2 clinical trial compares NNC0662-0419 with placebo and an approved diabetes medication called semaglutide. The goal is to find out if NNC0662-0419 is effective and safe for lowering blood sugar in people with type 2 diabetes. Participants will receive one of three treatments NNC0662-0419, semaglutide, or placebo. All treatments are given once weekly by injection under the skin. NNC0662-0419 will be given in increasing doses during the study. Semaglutide and placebo will also be given by weekly injections to match the other groups. Treatment assignment is random and participants will not know which treatment they receive. During the study, participants will be monitored regularly for changes in blood sugar levels measured by glycated hemoglobin HbA1c at weeks 16, 28, and 40. Additional assessments include body weight, fasting glucose, cholesterol levels, kidney function, waist size, inflammatory markers, and safety through adverse event tracking. The study lasts about 40 weeks of treatment with follow-up to week 44 to evaluate effects and safety.

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes